Trial Profile
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms PROLONG
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 24 Dec 2021 This study has been completed in Belgium as per European Clinical Trials Database.
- 12 Apr 2019 Status changed from completed to discontinued.
- 10 Sep 2018 This study has been Discontinued in Netherlands.